Daniele Rossini
About
Daniele Rossini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Daniele Rossini has authored 86 papers receiving a total of 799 indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Daniele Rossini's work include Colorectal Cancer Treatments and Studies (74 papers), Lung Cancer Treatments and Mutations (25 papers) and Gastric Cancer Management and Outcomes (23 papers). Daniele Rossini is often cited by papers focused on Colorectal Cancer Treatments and Studies (74 papers), Lung Cancer Treatments and Mutations (25 papers) and Gastric Cancer Management and Outcomes (23 papers). Daniele Rossini collaborates with scholars based in Italy, United States and Japan. Daniele Rossini's co-authors include Chiara Cremolini, Gianluca Masi, Alfredo Falcone, Carlotta Antoniotti, Federica Marmorino, Sara Lonardi, Filippo Pietrantonio, Fotios Loupakis, Roberto Moretto and Francesca Bergamo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Daniele Rossini
78 papers receiving 789 citations
Peers
Daniele Rossini
Isabelle Baumgaertner France
Alberto F. Sobrero Italy
Martin Maus Germany
Briant Fruth United States
Alice Zervoudakis United States
E Popa United States
Marisa Di Seri Italy
Beatrice Borelli Italy
F. Bertheault-Cvitkovic France
Monica Lencioni Italy
Citations per year, relative to Daniele Rossini Daniele Rossini (= 1×)
peers
Isabelle Baumgaertner
Countries citing papers authored by Daniele Rossini
Since
Specialization
Citations
This map shows the geographic impact of Daniele Rossini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniele Rossini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniele Rossini more than expected).
Fields of papers citing papers by Daniele Rossini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniele Rossini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniele Rossini. The network helps show where Daniele Rossini may publish in the future.
Co-authorship network of co-authors of Daniele Rossini
This figure shows the co-authorship network connecting the top 25 collaborators of Daniele Rossini. A scholar is included among the top collaborators of Daniele Rossini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniele Rossini. Daniele Rossini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.
2.
Antoniotti, Carlotta, Federica Marmorino, Daniele Rossini, et al.. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 228. 115713–115713.
3.
Bond, Marinde J. G., Maarten van Smeden, Koen Degeling, et al.. (2024). Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. JCO Clinical Cancer Informatics. 8(8). e2400037–e2400037.
4.
Conca, Veronica, Paola Vignali, Daniele Rossini, et al.. (2024). Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.. Journal of Clinical Oncology. 42(16_suppl). 3572–3572.
5.
Salani, Francesca, Daniele Rossini, Valentina Massa, et al.. (2024). Network meta‐analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence. Liver International. 44(10). 2763–2772.
6.
Rossini, Daniele, Alessandra Boccaccino, Carlotta Antoniotti, et al.. (2023). Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. European Journal of Cancer. 184. 106–116.
7.
Fanotto, V., Daniele Rossini, Mariaelena Casagrande, et al.. (2023). Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies. Cancers. 15(22). 5451–5451.
8.
Marmorino, Federica, Gianmarco Piccinno, Daniele Rossini, et al.. (2023). Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.. Journal of Clinical Oncology. 41(16_suppl). 3534–3534.
9.
Antoniotti, Carlotta, Daniele Rossini, Filippo Pietrantonio, et al.. (2023). SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study. Annals of Oncology. 34. S173–S174.
10.
Rossini, Daniele, et al.. (2022). 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study. Annals of Oncology. 33. S704–S704.
11.
Moretto, Roberto, Daniele Rossini, Iolanda Capone, et al.. (2021). Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer. 20(4). 314–317.
12.
Liu, Yingmiao, Jing Lyu, Kirsten B. Burdett, et al.. (2020). Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. Molecular Cancer Therapeutics. 19(10). 2146–2154.
13.
Antoniotti, Carlotta, Roberto Moretto, Daniele Rossini, et al.. (2020). Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews. 92. 102135–102135.
14.
Rossini, Daniele, Filippo Pagani, Antonio Pellino, et al.. (2019). Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Annals of Oncology. 30. iv118–iv118.
15.
Carbone, Carmine, Geny Piro, Francesca Simionato, et al.. (2017). Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research. 23(15). 4312–4322.
16.
Catalano, Vincenzo, Francesca Bergamo, Chiara Cremolini, et al.. (2017). Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. Annals of Oncology. 28. vi3–vi3.
17.
Antoniotti, Carlotta, Federica Marmorino, Marzia Pennati, et al.. (2017). Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. vi4–vi4.
18.
Santini, Daniele, Chiara Cremolini, Lisa Salvatore, et al.. (2017). Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO. Annals of Oncology. 28. vi9–vi9.
19.
Vincenzi, Bruno, Chiara Cremolini, Andrea Sartore‐Bianchi, et al.. (2015). Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. Annals of Oncology. 26. vi38–vi38.
20.
Cremolini, Chiara, Fotios Loupakis, Daniele Rossini, et al.. (2014). Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis. Annals of Oncology. 25. iv175–iv175.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Isabelle Baumgaertner Breakdown of academic impact, for papers by Alberto F. Sobrero Breakdown of academic impact, for papers by Martin Maus Breakdown of academic impact, for papers by Briant Fruth Breakdown of academic impact, for papers by Alice Zervoudakis Breakdown of academic impact, for papers by E Popa Breakdown of academic impact, for papers by Marisa Di Seri Breakdown of academic impact, for papers by Beatrice Borelli Breakdown of academic impact, for papers by F. Bertheault-Cvitkovic Breakdown of academic impact, for papers by Monica Lencioni